These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22303947)

  • 21. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy.
    Sun W; Oates PJ; Coutcher JB; Gerhardinger C; Lorenzi M
    Diabetes; 2006 Oct; 55(10):2757-62. PubMed ID: 17003340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor.
    Calcutt NA; Freshwater JD; Mizisin AP
    Diabetologia; 2004 Apr; 47(4):718-24. PubMed ID: 15298349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effect of Tephrosia purpurea in diabetic cataract through aldose reductase inhibitory activity.
    Bhadada SV; Vyas VK; Goyal RK
    Biomed Pharmacother; 2016 Oct; 83():221-228. PubMed ID: 27372406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of human aldehyde reductase: characterization of the active site pocket.
    Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
    Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual action spirobicycloimidazolidine-2,4-diones: antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications.
    Iqbal Z; Ali S; Iqbal J; Abbas Q; Qureshi IZ; Hameed S
    Bioorg Med Chem Lett; 2013 Jan; 23(2):488-91. PubMed ID: 23246355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(Aroyl)-N-(arylmethyloxy)-α-alanines: Selective inhibitors of aldose reductase.
    Nencetti S; La Motta C; Rossello A; Sartini S; Nuti E; Ciccone L; Orlandini E
    Bioorg Med Chem; 2017 Jun; 25(12):3068-3076. PubMed ID: 28392277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldose reductase and its inhibition in the control of diabetic complications.
    Narayanan S
    Ann Clin Lab Sci; 1993; 23(2):148-58. PubMed ID: 8457142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation on SIRT1-PGC-1α/Nrf2 pathway together with selective inhibition of aldose reductase makes compound hr5F a potential agent for the treatment of diabetic complications.
    Wang Z; Yuan S; Li Y; Zhang Z; Xiao W; Tang D; Ye K; Liu Z; Wang C; Zheng Y; Nie H; Chen H
    Biochem Pharmacol; 2018 Apr; 150():54-63. PubMed ID: 29371030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidized aldose reductase: in vivo factor not in vitro artifact.
    Grimshaw CE; Lai CJ
    Arch Biochem Biophys; 1996 Mar; 327(1):89-97. PubMed ID: 8615700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldose reductase inhibitors: recent developments.
    Sarges R; Oates PJ
    Prog Drug Res; 1993; 40():99-161. PubMed ID: 8356214
    [No Abstract]   [Full Text] [Related]  

  • 31. Prospecting for novel plant-derived molecules of Rauvolfia serpentina as inhibitors of Aldose Reductase, a potent drug target for diabetes and its complications.
    Pathania S; Randhawa V; Bagler G
    PLoS One; 2013; 8(4):e61327. PubMed ID: 23613832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical potential of aldose reductase inhibitors in diabetic neuropathy.
    Hamada Y; Nakamura J
    Treat Endocrinol; 2004; 3(4):245-55. PubMed ID: 16026107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
    Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
    Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artificial neural networks-based approach to design ARIs using QSAR for diabetes mellitus.
    Patra JC; Singh O
    J Comput Chem; 2009 Nov; 30(15):2494-508. PubMed ID: 19373836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo inhibition of aldose reductase and advanced glycation end products by phloretin, epigallocatechin 3-gallate and [6]-gingerol.
    Sampath C; Sang S; Ahmedna M
    Biomed Pharmacother; 2016 Dec; 84():502-513. PubMed ID: 27685794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aldose Reductase as a Drug Target for Treatment of Diabetic Nephropathy: Promises and Challenges.
    ElGamal H; Munusamy S
    Protein Pept Lett; 2017; 24(1):71-77. PubMed ID: 27894247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All in the family.
    Harrison DH
    Nat Struct Biol; 1995 Sep; 2(9):719-20. PubMed ID: 7552737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors.
    Ovais S; Pushpalatha H; Reddy GB; Rathore P; Bashir R; Yaseen S; Dheyaa A; Yaseen R; Tanwar O; Akthar M; Samim M; Javed K
    Eur J Med Chem; 2014 Jun; 80():209-17. PubMed ID: 24780598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of an aldose reductase inhibitor site by affinity labeling.
    Kador PF; Lee YS; Rodriguez L; Sato S; Bartoszko-Malik A; Abdel-Ghany YS; Miller DD
    Bioorg Med Chem; 1995 Oct; 3(10):1313-24. PubMed ID: 8564397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.
    van Gerven JM; Tjon-A-Tsien AM
    Drugs Aging; 1995 Jan; 6(1):9-28. PubMed ID: 7696781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.